How to Give Yourself the Best Shot at Living to 150+

Siim explains that cardiovascular disease kills up to 33% of people and often presents with no warning—the first sign is a heart attack with roughly 50% survival. The disease silently progresses over decades, so early prevention is the only way to avoid becoming a statistic. He endorses a Mediterranean-style diet as a well-proven, non-experimental approach. Routine blood work allows early detection of inflammation (CRP), elevated glucose, blood pressure, and lipids—all silent drivers. For those over 50, a coronary CT scan can visualize plaque and its severity, enabling targeted lifestyle or pharmacological interventions. By aggressively managing these factors, you remove the biggest roadblock to reaching 100+, buying time for future anti-aging therapies.

Siim paints aging as a gradual withdrawal from a bank of physiological and social resources. He argues that by maximizing peak bone density, muscle mass, cognitive function, and social networks early on, you can delay the point at which decline becomes disabling or fatal. Cognitive reserve, built via education and novelty, helps the brain compensate for neurodegenerative pathology. Bone density and muscle strength, built through resistance training, protect against hip fractures—a leading killer in the elderly—and frailty. Social capital increases life satisfaction, which correlates with longevity. This proactive, reserve-focused approach complements his other protocols by ensuring you arrive at old age with more capacity to survive health shocks.

Siim stresses that longevity isn't just about biology—it's also about not dying prematurely from avoidable causes. He cites statistics: motorcyclists are 24 times more likely to die than car occupants; falls become a bigger threat with age; drug overdose and traffic accidents disproportionately kill younger people. He urges simple precautions: wear protective gear, avoid speeding and drunk driving, quit drugs, and even check home safety (stove kill switch, no dangerous hanging objects). The message is that longevity requires surviving long enough for future medicine, so risk reduction is foundational.

Siim acknowledges the allure of cutting-edge interventions but draws a hard line: today’s gene therapies are a gamble with no upside and serious downsides. He describes typical offerings costing $25–50k at offshore clinics with no regulatory oversight. At best, you get saline; at worst, severe infection or unknown long-term harm. He still believes gene editing is the key to living past 120, but says we must wait for the science to mature. He offers a pragmatic age-based decision framework: if you're 80, you may rationally accept the risk because time is running out; if you're younger, patience is the smarter longevity play.

Siim positions rapamycin as the most robust candidate for human lifespan extension, given its consistent results across animal models. However, he points to the ongoing companion dog study as the best upcoming data set for translational insight. He has decided to pause his own use and even delay giving it to his dog until the study concludes. He also notes that even late-life rapamycin extended mouse lifespan by 9–14%, suggesting that starting later might still be beneficial, which provides hope for older individuals who can't afford to wait. This wait-and-see protocol is presented as a rational middle ground between refusal and reckless experimentation.

Siim extends the longevity lens to the built environment. He advises choosing a residence with low outdoor pollution and then fortifying the indoors with air and water filtration, house plants for air purification, and mold inspections—especially in water-damaged buildings. He also mentions practical safety measures like a kill switch for kitchen appliances and avoiding precarious decorations (the Sword of Damocles analogy). These measures may seem trivial, but he argues that minimizing environmental hazards is an underrated longevity lever.

Siim simplifies the organic food debate with a practical heuristic: only worry about the skins you consume. He explains that some pesticides have been associated with higher cancer and neurodegeneration risk. Foods like bananas, which are peeled, have minimal exposure, while berries and apples (eaten whole) warrant organic choices. This rule-of-thumb avoids the cost and complexity of buying everything organic.

Siim opens by explaining de Grey’s concept and prediction, then offers his own forecast. He believes 2036 is too early, but 2045 might be possible with a 5–10% probability. He stresses that even if escape velocity is missed, more people will still reach 100–120 thanks to incremental medical advances. For him personally, 2045 would make him 50—still young—but if it happens in 2075 he’ll be 80. Hence the entire video’s premise: stay healthy now so you’re still around when the therapies mature, whenever that is.

Siim explains that up to 33% of people die from cardiovascular disease, and the average first heart attack occurs at 65. He warns that the disease develops silently over decades, so the first symptom is often a life-threatening event with only 50/50 survival. By viewing it as a bottleneck, he argues that removing it through prevention would extend life expectancy by 5–10 years, enough to bridge the gap to future longevity therapies. This insight makes heart disease prevention a central, non-negotiable pillar of his longevity plan.

Siim argues that you can slow the rate of decline by maximizing reserves when you’re younger. For the brain, people with higher cognitive reserve—built through education, learning, and novelty—fare better against dementia. For the body, stronger individuals have lower all-cause mortality, and higher bone density reduces the risk of fatal hip fractures. Social capital, he says, improves life satisfaction and happiness. By viewing these as deposits into a savings account, he encourages early, consistent investment so you can draw on them later when natural decline accelerates.

He states that as of 2025, there is no evidence any gene therapy extends human lifespan. The worst case is infection or shortened lifespan, the best case is just saline. Yet he concedes that gene editing will be required to push lifespan beyond 120—exercise and diet alone won’t do it. His advice is stratified: if you’re young (under 60), the smart move is to wait 10–20 years for safer, more effective versions. If you’re 80, the gamble might be worth it because you have less to lose, but caution is still warranted. This pragmatic, timeline-aware stance sets him apart from both extreme proponents and dismissive skeptics.

Siim calls rapamycin the most likely candidate to extend human lifespan based on animal data. However, he cites the ongoing companion dog trial led by Dr. Matt Kaeberlein, which will provide translational data in a longer-lived mammal. He’s decided to wait for those results before starting himself or giving it to his dog. He also notes that even late-life administration in mice gave a 14% lifespan boost in females and 9% in males, implying the window of opportunity may extend into old age. This strategy balances optimism about the drug with a respect for uncertainty.